



King's Research Portal

DOI:

[10.1093/ecco-jcc/jjac116](https://doi.org/10.1093/ecco-jcc/jjac116)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Honap, S., Irving, P. M., & Samaan, M. A. (2022). Ustekinumab-Induced Inflammatory Demyelinating Polyneuropathy in a Patient with Ulcerative Colitis. *Journal Of Crohns & Colitis*. Advance online publication. <https://doi.org/10.1093/ecco-jcc/jjac116>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Ustekinumab-Induced Inflammatory Demyelinating Polyneuropathy in a Patient with Ulcerative Colitis

Sailish Honap^{1,2}, Peter M Irving^{1,2}, Mark A Samaan¹

¹IBD Centre, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, UK

²School of Immunology and Microbial Sciences, King's College London, UK

Corresponding author:

Dr Sailish Honap, IBD Centre, 1st Floor College House, South Wing, St. Thomas' Hospital,

Westminster Bridge Rd, London SE1 7EH. Email: shonap@nhs.net Tel: 020 7188 2497

SHORT TITLE

Ustekinumab-Induced Demyelinating Polyneuropathy

FUNDING

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

ETHICS

Full informed consent was provided by patient

AUTHOR CONTRIBUTIONS

SH prepared the initial manuscript draft and all authors critically reviewed the manuscript before submission.

CONFLICT OF INTEREST STATEMENT

SH has served as a speaker, a consultant and/or advisory board member for Pfizer, Janssen, Abbvie, and Takeda. PI has received lecture fees from Abbvie, Warner Chilcott, Ferring, Falk Pharma, Takeda, MSD, Johnson and Johnson, Shire, and Pfizer. Financial support for research: MSD, Takeda, and Pfizer. Advisory fees: Abbvie, Warner Chilcott, Takeda, MSD, Vifor Pharma, Pharmacosmos, Topivert, Genentech, Hospira, and Samsung Bioepis. MAS has served as a speaker, a consultant, and/or an advisory board member for Sandoz, Janssen, Takeda, MSD, Falk, Abbvie, Bristol Myers Squibb, Galapagos, and Samsung Bioepis.

KEY WORDS

Ustekinumab, peripheral neuropathy, demyelination, sub-acute inflammatory demyelinating polyneuropathy, SIDP

WORD COUNT

403 words

To the Editors,

Ustekinumab, a monoclonal antibody targeting interleukin-12/23, is the latest biologic approved for the treatment of moderate-to-severe ulcerative colitis (UC). Although anti-tumour necrosis factor (TNF) agents are associated with central and peripheral nervous system demyelination, neurological complications of ustekinumab are exceptionally rare.¹ In pooled analyses of 12 ustekinumab registrational trials with 5884 patients and 4521 patient-years follow up, there were no cases of demyelinating disorders.² We report only the third known case of ustekinumab-induced demyelination in a patient with active UC.^{3,4}

An otherwise well 48-year-old female, with a 30 year history of left-sided UC, was treated with adalimumab in 2016 following thiopurine intolerance. Three months after dose escalation for sub-therapeutic levels, she developed paraesthesia in her hands and feet and electromyography (EMG) with nerve conduction studies (NCS) revealed features consistent with a demyelinating polyneuropathy. Adalimumab was discontinued and six weeks later she made a complete neurological recovery with conservative management without recrudescence.

In July 2021, following loss of response to vedolizumab and severe colitis (Mayo 3) on endoscopic assessment, ustekinumab was commenced. Five days following the induction infusion, she again developed paraesthesia affecting all four limbs. On this occasion, muscle weakness was more pronounced, affecting fine motor hand function and her ability to ambulate and maintain balance. Symptoms progressed and specialist neurological review revealed a symmetrical, non-length-dependent weakness, reduced sensation, and

hyporeflexia. Investigations showed raised cerebrospinal fluid protein of 0.84g/L (normal 0-0.44) and marked peripheral nerve demyelination on EMG and NCS, in keeping with a diagnosis of sub-acute inflammatory demyelinating polyneuropathy (SIDP). Infection and autoimmune screens were negative, and neuroimaging of the brain and spinal cord were also unremarkable. Ustekinumab discontinuation and intravenous immunoglobulin infusions over eight weeks led to significant improvement with resolution of neurological symptoms. Repeat neurophysiology testing six months later confirmed improvement in sensorimotor responses in upper and lower limbs.

SIDP is a rare immune-mediated disorder characterised by axonal damage and peripheral nerve demyelination, resulting in muscle weakness and impaired sensory function. There is an increased risk of demyelinating diseases in patients with IBD.⁵ Proving causality is difficult as the observed association could be the unmasking of a latent demyelinating disease or the emergence of a *de novo* demyelinating process. However, the temporal association and marked clinical and objective improvement following drug withdrawal, favours a drug-induced illness. While ustekinumab has a favourable safety profile, this case demonstrates a rare neurological side effect more typically associated with anti-TNF therapy.

ACKNOWLEDGMENTS

Nil

REFERENCES

1. Stübgen J-P. Tumor necrosis factor-alpha antagonists and neuropathy. *Muscle Nerve*. 2008 Mar;37(3):281–92.
2. Ghosh S, Gensler LS, Yang Z, et al. Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs. *Drug Saf*. 2019 Jun;42(6):751–68.
3. Badat Y, Meissner WG, Laharie D. Demyelination in a patient receiving ustekinumab for refractory Crohn’s disease. *Journal of Crohn’s and Colitis*. 2014 Sep 1;8(9):1138–9.
4. Osman G, Shah K, Khan MS, et al. Ustekinumab related CIDP in a patient with psoriatic arthritis (P2.451). *Neurology [Internet]*. 2018 Apr 10 [cited 2021 Nov 1];90(15 Supplement). Available from: https://n.neurology.org/content/90/15_Supplement/P2.451
5. Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. *Gastroenterology*. 2005 Sep;129(3):819-26.